| (Values in U.S. Thousands) | Mar, 2020 | Dec, 2019 | Sep, 2019 | Jun, 2019 | Mar, 2019 |
| Sales | 0 | 10 | 10 | 10 | 10 |
| Sales Growth | -100.00% | unch | unch | unch | -50.00% |
| Net Income | -10,280 | -10,580 | -18,740 | -17,110 | -17,080 |
| Net Income Growth | +2.84% | +43.54% | -9.53% | -0.18% | +12.81% |
Tocagen Inc (TOCA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States.